.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

ACTRIMS 2020: Post-Conference Perspectives

EP. 1: ACTRIMS 2020 News Network: CLARITY Study on Relapsing Multiple Sclerosis

March 14th 2020

EP. 2: ACTRIMS 2020 News Network: Updated Data From the CLARITY Study

March 14th 2020

EP. 3: ACTRIMS 2020 News Network: EXPAND Study on Relapsing MS

March 14th 2020

EP. 4: ACTRIMS 2020 News Network: Effect of Disease Duration in the EXPAND Study

March 14th 2020

EP. 5: ACTRIMS 2020 News Network: OPERA I/II Trials on Relapsing MS

March 14th 2020

EP. 6: ACTRIMS 2020 News Network: 6-Year Data With Ocrelizumab

March 14th 2020

EP. 7: ACTRIMS 2020 News Network: APLIOS Bioequivalence Study on Relapsing MS

March 14th 2020

EP. 8: ACTRIMS 2020 News Network: B-Cell Depletion in the Phase 2 APLIOS Study

March 14th 2020

EP. 9: ACTRIMS 2020 News Network: Updated Recommendations for Standardized MRI Protocol in MS

March 14th 2020

EP. 10: ACTRIMS 2020 News Network: Standardized MRI Protocol for MS

March 14th 2020

Latest News

The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley

American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage

FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine

Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD

View More News